Selenium enhances the efficacy of Radachlorin mediated-photodynamic therapy in TC-1 tumor development

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 576-584

  Kim, Yong Wan ^a   Bae, Su Mi ^a   Liu, Hai Bo ^a   Kim, In Wook ^a   Chun, Heung Jae ^b   Ahn, Woong Shick ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Anti cancer therapy; Combination therapy; Photodynamic therapy; Selenium

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOLIPASE C; PHOTOSENSITIZING AGENT; PROTEIN FOS; PROTEIN MDM2; PROTEIN P53; RADACHLORIN; SELENIUM; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

ANIMALS; CELL GROWTH PROCESSES; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; SELENIUM;

EID: 84863441926     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1820     Document Type: Article

References (32)

1. Dolmans DE, Fukumura D and Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer 3: 380-387, 2003. (Pubitemid 37328858)
2. Moghissi K, Dixon K, Thorpe JA, Stringer M and Oxtoby C: Photodynamic therapy (PDT) in early central lung cancer: a treatment option for patients ineligible for surgical resection. Thorax 62: 391-395, 2007. (Pubitemid 46698386)
3. Usuda J, Kato H, Okunaka T, et al: Photodynamic therapy (PDT) for lung cancers. J Thorac Oncol 1: 489-493, 2006. (Pubitemid 47181428)
4. Klein A, Babilas P, Karrer S, Landthaler M and Szeimies RM: Photodynamic therapy in dermatology - an update 2008. J Dtsch Dermatol Ges 6: 839-846, 2008.
5. Biel MA: Photodynamic therapy treatment of early oral and laryngeal cancers. Photochem Photobiol 83: 1063-1068, 2007. (Pubitemid 47438525)
6. Dougherty TJ, Gomer CJ, Henderson BW, et al: Photodynamic therapy. J Natl Cancer Inst 90: 889-905, 1998. (Pubitemid 28304157)
7. Gollnick SO, Evans SS, Baumann H, et al: Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 88: 1772-1779, 2003. (Pubitemid 36760423)
8. Harrison L and Blackwell K: Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9 (Suppl 5): 31-40, 2004. (Pubitemid 39658343)
9. Vaupel P and Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9 (Suppl. 5): 4-9, 2004. (Pubitemid 39658340)
10. Stadtman TC: Selenium biochemistry. Mammalian selenoenzymes. Ann NY Acad Sci 899: 399-402, 2000.
11. Navarro-Alarcon M and Cabrera-Vique C: Selenium in food and the human body: a review. Sci Total Environ 400: 115-141, 2008.
12. Jackson MI and Combs GF Jr: Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 11: 718-726, 2008.
13. Letavayova L, Vlckova V and Brozmanova J: Selenium: from cancer prevention to DNA damage. Toxicology 227: 1-14, 2006. (Pubitemid 44402853)
14. Pletcher SD, Macdonald SJ, Marguerie R, et al: Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol 12: 712-723, 2002. (Pubitemid 34455424)
15. Wang JL, Lin YW, Chen HM, et al: Calcium prevents tumorigenesis in a mouse model of colorectal cancer. PLoS One 6: e22566, 2011.
16. Wilson BC and Patterson MS: The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 53: R61-R109, 2008. (Pubitemid 351570924)
17. Zawacka-Pankau J, Krachulec J, Grulkowski I, Bielawski KP and Selivanova G: The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances. Toxicol Appl Pharmacol 232: 487-497, 2008.
18. Buytaert E, Dewaele M and Agostinis P: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776: 86-107, 2007. (Pubitemid 47332075)
19. Milde-Langosch K: The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41: 2449-2461, 2005.
20. Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP and Liang HJ: Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy 54: 357-363, 2008.
21. Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG and Gorter A: The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol 208: 507-517, 2006. (Pubitemid 43329337)
22. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ and Scheffner M: Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 98: 1218-1223, 2001. (Pubitemid 32121213)
23. Ferrario A, Von Tiehl K, Wong S, Luna M and Gomer CJ: Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 62: 3956-3961, 2002. (Pubitemid 34791059)
24. Bequet-Romero M and Lopez-Ocejo O: Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun 277: 55-61, 2000.
25. Karamysheva AF: Mechanisms of angiogenesis. Biochemistry (Mosc) 73: 751-762, 2008.
26. Deng CX: BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34: 1416-1426, 2006.
27. Yen CY, Chen CH, Chang CH, et al: Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. Biomarkers 14: 244-249, 2009.
28. Wu TC: The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 67: 6003-6006, 2007.
29. Zender L, Spector MS, Xue W, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125: 1253-1267, 2006. (Pubitemid 43929093)
30. Ma O, Cai WW, Zender L, et al: MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 69: 2559-2567, 2009.
31. Khor TO, Gul YA, Ithnin H and Seow HF: A comparative study of the expression of Wnt-1, WISP-1, survivin and cyclin-D1 in colorectal carcinoma. Int J Colorectal Dis 21: 291-300, 2006. (Pubitemid 43880533)
32. Xie D, Nakachi K, Wang H, Elashoff R and Koeffler HP: Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61: 8917-8923, 2001. (Pubitemid 34013909)